Neurodegeneration and chronic renal failure in methylmalonic aciduria--a pathophysiological approach.
In the last decades the survival of patients with methylmalonic aciduria has been improved. However, the overall outcome of affected patients remains disappointing. The disease course is often complicated by acute life-threatening metabolic crises, which can result in multiple organ failure or even death, resembling primary defects of mitochondrial energy metabolism. Biochemical abnormalities during metabolic derangement, such as metabolic acidosis, ketonaemia/ketonuria, lactic acidosis, hypoglycaemia and hyperammonaemia, suggest mitochondrial dysfunction. In addition, long-term complications such as chronic renal failure and neurological disease are frequently found. Neuropathophysiological studies have focused on various effects caused by accumulation of putatively toxic organic acids, the so-called 'toxic metabolite' hypothesis. In previous studies, methylmalonate (MMA) has been considered as the major neurotoxin in methylmalonic aciduria, whereas more recent studies have highlighted a synergistic inhibition of mitochondrial energy metabolism (pyruvate dehydrogenase complex, tricarboxylic acid cycle, respiratory chain, mitochondrial salvage pathway of deoxyribonucleoside triphosphate (dNTP)) induced by propionyl-CoA, 2-methylcitrate and MMA as the key pathomechanism of inherited disorders of propionate metabolism. Intracerebral accumulation of toxic metabolites ('trapping' hypothesis') is considered a biochemical risk factor for neurodegeneration. Secondary effects of mitochondrial dysfunction, such as oxidative stress and impaired mtDNA homeostasis, contribute to pathogenesis of these disorders. The underlying pathomechanisms of chronic renal insufficiency in methylmalonic acidurias are not yet understood. We hypothesize that renal and cerebral pathomechanisms share some similarities, such as an involvement of dicarboxylic acid transport. This review aims to give a comprehensive overview on recent pathomechanistic concepts for methylmalonic acidurias.
Morath
M A
MA
Department of General Pediatrics, Division of Inherited Metabolic Diseases, University Children's Hospital Heidelberg, Im Neuenheimer Feld 150, 69120, Heidelberg, Germany. marina.morath@med.uni-heidelberg.de
Okun
J G
JG
Müller
I B
IB
Sauer
S W
SW
Hörster
F
F
Hoffmann
G F
GF
Kölker
S
S
D000818:Animals; D001921:Brain / Q000378:metabolism / Q000503:physiopathology; D003998:Dicarboxylic Acids / Q000378:metabolism; D004734:Energy Metabolism / Q000502:physiology; D006801:Humans; D007668:Kidney / Q000378:metabolism / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D008764:Methylmalonic Acid / Q000652:urine*; D008928:Mitochondria / Q000378:metabolism; D008954:Models, Biological; D019636:Neurodegenerative Diseases / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D014806:Vitamin B 12 Deficiency / Q000150:complications* / Q000378:metabolism / Q000652:urine
D003998:Dicarboxylic Acids; D008764:Methylmalonic Acid